Early onset of autoimmunity in MRL/++ mice following immunization with β2 glycoprotein I

A. L. Aron, M. L. Cuellar, Robin L Brey, S. McKeown, L. R. Espinoza, Y. Shoenfeld, A. E. Gharavi

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Antiphospholipid antibodies (aPL) are associated with thrombosis, thrombocytopenia and recurrent fetal loss in humans and in some animal models. Immunization with β2 glycoprotein I (β2GPI) induced aPL production in normal rabbits and mice. However, the association of these antibodies with disease manifestations remains controversial. To determine whether induction of aPL by β2GPI immunization in an autoimmune strain of mice (MRL/++) would result in acceleration of clinical and serological autoimmune disease manifestations, three groups of 8-week-old female mice were studied. One group was immunized with β2GPI, and one with ovalbumin (OVA); the third was not immunized. After two booster injections, sera presence of anticardiolipin (aCL) and anti-DNA by ELISA and anti-nuclear antibody (ANA) by immunofluorescence. Mice were studied for thrombocytopenia, proteinuria, fecundity rates, litter sizes and the development of central nervous system dysfunction. Elevated levels of aCL, anti-DNA and ANA were detected in all β2GPI-immunized, in three OVA-immunized, and in none of the unimmunized mice. The anti-DNA antibodies were inhibited by CL micelles, suggesting crossreactivity between aCL and anti-DNA. Platelet counts, fecundity rates and litter size were reduced in β2GPI-immunized but not in OVA-immunized or unimmunized mice. None of the mice developed neurological dysfunction or significant proteinuria over a 10-week period post-immunization. These findings suggest that β2GPI immunization induces aPL in MRL/++ mice associated with accelerated autoimmune manifestations resembling the antiphospholipid syndrome.

Original languageEnglish (US)
Pages (from-to)78-81
Number of pages4
JournalClinical and Experimental Immunology
Volume101
Issue number1
StatePublished - 1995
Externally publishedYes

Fingerprint

Autoimmunity
Immunization
Glycoproteins
Antiphospholipid Antibodies
Ovalbumin
Litter Size
Antinuclear Antibodies
Proteinuria
Thrombocytopenia
Fertility
Antiphospholipid Syndrome
DNA
Micelles
Platelet Count
Autoimmune Diseases
Antibody Formation
Fluorescent Antibody Technique
Anti-Idiotypic Antibodies
Thrombosis
Central Nervous System

Keywords

  • β glycoprotein I
  • Antiphospholipid antibodies
  • Antiphospholipid syndrome
  • Fetal death
  • Thrombocytopenia

ASJC Scopus subject areas

  • Immunology

Cite this

Aron, A. L., Cuellar, M. L., Brey, R. L., McKeown, S., Espinoza, L. R., Shoenfeld, Y., & Gharavi, A. E. (1995). Early onset of autoimmunity in MRL/++ mice following immunization with β2 glycoprotein I. Clinical and Experimental Immunology, 101(1), 78-81.

Early onset of autoimmunity in MRL/++ mice following immunization with β2 glycoprotein I. / Aron, A. L.; Cuellar, M. L.; Brey, Robin L; McKeown, S.; Espinoza, L. R.; Shoenfeld, Y.; Gharavi, A. E.

In: Clinical and Experimental Immunology, Vol. 101, No. 1, 1995, p. 78-81.

Research output: Contribution to journalArticle

Aron, AL, Cuellar, ML, Brey, RL, McKeown, S, Espinoza, LR, Shoenfeld, Y & Gharavi, AE 1995, 'Early onset of autoimmunity in MRL/++ mice following immunization with β2 glycoprotein I', Clinical and Experimental Immunology, vol. 101, no. 1, pp. 78-81.
Aron, A. L. ; Cuellar, M. L. ; Brey, Robin L ; McKeown, S. ; Espinoza, L. R. ; Shoenfeld, Y. ; Gharavi, A. E. / Early onset of autoimmunity in MRL/++ mice following immunization with β2 glycoprotein I. In: Clinical and Experimental Immunology. 1995 ; Vol. 101, No. 1. pp. 78-81.
@article{701660cadaf743e4af758afdcade57e5,
title = "Early onset of autoimmunity in MRL/++ mice following immunization with β2 glycoprotein I",
abstract = "Antiphospholipid antibodies (aPL) are associated with thrombosis, thrombocytopenia and recurrent fetal loss in humans and in some animal models. Immunization with β2 glycoprotein I (β2GPI) induced aPL production in normal rabbits and mice. However, the association of these antibodies with disease manifestations remains controversial. To determine whether induction of aPL by β2GPI immunization in an autoimmune strain of mice (MRL/++) would result in acceleration of clinical and serological autoimmune disease manifestations, three groups of 8-week-old female mice were studied. One group was immunized with β2GPI, and one with ovalbumin (OVA); the third was not immunized. After two booster injections, sera presence of anticardiolipin (aCL) and anti-DNA by ELISA and anti-nuclear antibody (ANA) by immunofluorescence. Mice were studied for thrombocytopenia, proteinuria, fecundity rates, litter sizes and the development of central nervous system dysfunction. Elevated levels of aCL, anti-DNA and ANA were detected in all β2GPI-immunized, in three OVA-immunized, and in none of the unimmunized mice. The anti-DNA antibodies were inhibited by CL micelles, suggesting crossreactivity between aCL and anti-DNA. Platelet counts, fecundity rates and litter size were reduced in β2GPI-immunized but not in OVA-immunized or unimmunized mice. None of the mice developed neurological dysfunction or significant proteinuria over a 10-week period post-immunization. These findings suggest that β2GPI immunization induces aPL in MRL/++ mice associated with accelerated autoimmune manifestations resembling the antiphospholipid syndrome.",
keywords = "β glycoprotein I, Antiphospholipid antibodies, Antiphospholipid syndrome, Fetal death, Thrombocytopenia",
author = "Aron, {A. L.} and Cuellar, {M. L.} and Brey, {Robin L} and S. McKeown and Espinoza, {L. R.} and Y. Shoenfeld and Gharavi, {A. E.}",
year = "1995",
language = "English (US)",
volume = "101",
pages = "78--81",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Early onset of autoimmunity in MRL/++ mice following immunization with β2 glycoprotein I

AU - Aron, A. L.

AU - Cuellar, M. L.

AU - Brey, Robin L

AU - McKeown, S.

AU - Espinoza, L. R.

AU - Shoenfeld, Y.

AU - Gharavi, A. E.

PY - 1995

Y1 - 1995

N2 - Antiphospholipid antibodies (aPL) are associated with thrombosis, thrombocytopenia and recurrent fetal loss in humans and in some animal models. Immunization with β2 glycoprotein I (β2GPI) induced aPL production in normal rabbits and mice. However, the association of these antibodies with disease manifestations remains controversial. To determine whether induction of aPL by β2GPI immunization in an autoimmune strain of mice (MRL/++) would result in acceleration of clinical and serological autoimmune disease manifestations, three groups of 8-week-old female mice were studied. One group was immunized with β2GPI, and one with ovalbumin (OVA); the third was not immunized. After two booster injections, sera presence of anticardiolipin (aCL) and anti-DNA by ELISA and anti-nuclear antibody (ANA) by immunofluorescence. Mice were studied for thrombocytopenia, proteinuria, fecundity rates, litter sizes and the development of central nervous system dysfunction. Elevated levels of aCL, anti-DNA and ANA were detected in all β2GPI-immunized, in three OVA-immunized, and in none of the unimmunized mice. The anti-DNA antibodies were inhibited by CL micelles, suggesting crossreactivity between aCL and anti-DNA. Platelet counts, fecundity rates and litter size were reduced in β2GPI-immunized but not in OVA-immunized or unimmunized mice. None of the mice developed neurological dysfunction or significant proteinuria over a 10-week period post-immunization. These findings suggest that β2GPI immunization induces aPL in MRL/++ mice associated with accelerated autoimmune manifestations resembling the antiphospholipid syndrome.

AB - Antiphospholipid antibodies (aPL) are associated with thrombosis, thrombocytopenia and recurrent fetal loss in humans and in some animal models. Immunization with β2 glycoprotein I (β2GPI) induced aPL production in normal rabbits and mice. However, the association of these antibodies with disease manifestations remains controversial. To determine whether induction of aPL by β2GPI immunization in an autoimmune strain of mice (MRL/++) would result in acceleration of clinical and serological autoimmune disease manifestations, three groups of 8-week-old female mice were studied. One group was immunized with β2GPI, and one with ovalbumin (OVA); the third was not immunized. After two booster injections, sera presence of anticardiolipin (aCL) and anti-DNA by ELISA and anti-nuclear antibody (ANA) by immunofluorescence. Mice were studied for thrombocytopenia, proteinuria, fecundity rates, litter sizes and the development of central nervous system dysfunction. Elevated levels of aCL, anti-DNA and ANA were detected in all β2GPI-immunized, in three OVA-immunized, and in none of the unimmunized mice. The anti-DNA antibodies were inhibited by CL micelles, suggesting crossreactivity between aCL and anti-DNA. Platelet counts, fecundity rates and litter size were reduced in β2GPI-immunized but not in OVA-immunized or unimmunized mice. None of the mice developed neurological dysfunction or significant proteinuria over a 10-week period post-immunization. These findings suggest that β2GPI immunization induces aPL in MRL/++ mice associated with accelerated autoimmune manifestations resembling the antiphospholipid syndrome.

KW - β glycoprotein I

KW - Antiphospholipid antibodies

KW - Antiphospholipid syndrome

KW - Fetal death

KW - Thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=0029074352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029074352&partnerID=8YFLogxK

M3 - Article

C2 - 7621596

AN - SCOPUS:0029074352

VL - 101

SP - 78

EP - 81

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 1

ER -